XML 70 R13.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Iloperidone Sublicense to Novartis Pharma AG | 12 Months Ended
--- | ---
Dec. 31, 2013
Iloperidone Sublicense to Novartis Pharma AG [Abstract] |
Iloperidone Sublicense to Novartis Pharma AG [Text Block] | 5. Iloperidone Sublicense to Novartis Pharma AG We are party to an agreement with Novartis, which, as amended, grants Novartis a worldwide sublicense to iloperidone (Fanapt®) in exchange for tiered royalties on net sales ranging from 8% to 10% and assumption of responsibility for all clinical development, registration, manufacturing and marketing of the product. Novartis currently has the right to commercialize Fanapt in the United States and Canada. Pursuant to agreements entered into during 2011,we sold substantially all of our remaining future royalties on the sales of Fanapt® to Deerfield, and accordingly the future royalty payments owed to us by Novartis will continue to be transmitted to Deerfield upon receipt from Novartis per the terms of the agreement with Deerfield. See Note 8, “Royalty Liability” for further discussion of our royalty liabilities.

X
- Details
Name: | ttnp_SublicenseAbstract
Namespace Prefix: | ttnp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sublicense. + References No definition available. + Details
Name: | ttnp_SublicenseTextBlock
Namespace Prefix: | ttnp_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration